Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Increased Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Cancer Patients

Dan Aderka, Hartmut Engelmann, Vered Hornik, Yehuda Skornick, Yoram Levo, David Wallach and Gil Kushtai
Dan Aderka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hartmut Engelmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vered Hornik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yehuda Skornick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoram Levo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Wallach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gil Kushtai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 1991
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Soluble forms of the two molecular species of the cell surface receptors for tumor necrosis factor (TNF) have been detected in normal urine. Using enzyme-linked immunosorbent assays for these soluble receptors, we determined their levels in the sera of 40 healthy subjects and 59 patients with solid tumors. The mean ± SD concentrations of both the soluble type I (p55) and type II (p75) receptors were significantly higher in the cancer patients than in the healthy controls: 1.96 ± 1.19 versus 0.79 ± 0.19 ng/ml (P < 0.001) and 6.43 ± 4.8 versus 3.2 ± 0.6 ng/ml (P < 0.001), respectively. The incidence and the extent of the increase correlated with the staging of disease. Sera of the cancer patients had a marked inhibitory effect on the in vitro cytocidal activity of TNF. This inhibition was proportional to the content of soluble TNF receptors and could be fully abolished by the addition to the sera of specific antibodies against the receptors. Among the cancer patients, the incidence of increase in the concentrations of soluble TNF receptors (about 70%) greatly exceeded that of the serum carcinoembryonic antigen (about 26%), a commonly used cancer marker. The origin of the serum soluble TNF receptors in cancer patients and the physiological implications of their effect on TNF function remain to be elucidated.

Footnotes

  • ↵1 This work was supported by a grant from Inter-Lab Ltd., Ness-Ziona, Israel, as well by a grant from the National Council for Research and Development, Israel, and the German Cancer Research Center.

  • ↵2 To whom requests for reprints should be addressed, at Department of Molecular Genetics and Virology, The Weizmann Institute of Science, Rehovot, 76100, Israel.

  • Received March 11, 1991.
  • Accepted August 1, 1991.
  • ©1991 American Association for Cancer Research.
PreviousNext
Back to top
October 1991
Volume 51, Issue 20
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Increased Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Cancer Patients
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Increased Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Cancer Patients
Dan Aderka, Hartmut Engelmann, Vered Hornik, Yehuda Skornick, Yoram Levo, David Wallach and Gil Kushtai
Cancer Res October 15 1991 (51) (20) 5602-5607;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Increased Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Cancer Patients
Dan Aderka, Hartmut Engelmann, Vered Hornik, Yehuda Skornick, Yoram Levo, David Wallach and Gil Kushtai
Cancer Res October 15 1991 (51) (20) 5602-5607;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Laminin Receptor Complementary DNA-deduced Synthetic Peptide Inhibits Cancer Cell Attachment to Endothelium
  • T-Cell Receptor Vβ Gene Expression Differs in Tumor-infiltrating Lymphocytes within Primary and Metastatic Melanoma
  • Acidic and Basic Fibrolast Growth Factors Are Present in Glioblastoma Multiforme
Show more Basic Sciences

Immunology

  • Abstract 6655: Tumor microenvironment evaluation and tumor intrinsic genomic features predict anti-PD-1 response of metastatic gastric cancer: Results from phase II clinical trial and multi-omics data
  • Abstract 6599: Screening and characterization of AlloCAR T targeting DLL3 for the treatment of small cell lung cancer
  • Abstract 6673: B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity
Show more Immunology

Articles

  • Imprinting of a Genomic Domain of 11p15 and Loss of Imprinting in Cancer: An Introduction
  • The Phenotypes Associated with ret Mutations in the Multiple Endocrine Neoplasia Type 2 Syndrome
  • Organizational Structure: General Motors Cancer Research Foundation
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement